Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 1845-1855

  Gootz, Thomas D ^a   Zaniewski, Richard P ^a   Haskell, Suzanne L ^a   Kaczmarek, Frank S ^a   Maurice, Alison E ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); LEVOFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; SPARFLOXACIN; TROVAFLOXACIN;

ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATION; DNA CLEAVAGE; DRUG POTENCY; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS;

EID: 0032840206     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.1845     Document Type: Article

References (42)

1. Barry, A. L., S. D. Brown, and P. C. Fuchs. 1996. In vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin. J. Antimicrob. Chemother. 38:324-327.
2. Blanche, F., B. Cameron, F.-X. Bernard, L. Maton, B. Manse, L. Ferrero, N. Ratet, C. Lecoq, A. Goniot, D. Bisch, and J. Crouzet. 1996. Differential behaviors of Staphylococcus aureus and Escherichia coli type II topoisomerases. Antimicrob. Agents Chemother. 40:2714-2720.
3. Bonilla, H. F., L. T. Zarins, S. F. Bradley, and C. A. Kauffman. 1996. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin. Diagn. Microbiol. Infect. Dis. 26:17-21.
4. Brenwald, N. P., M. J. Gill, and R Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
5. Brighty, K., and T. Gootz. 1997. Chemistry and biological profile of trovafloxacin. J. Antimicrob. Chemother. 39(Suppl. B):1-14.
6. Brockbank, S. M. V., and P. T. Barth. 1993. Cloning, sequencing, and expression of the DNA gyrase genes from Staphylococcus aureus. J. Bacteriol. 175:3269-3277.
7. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
8. Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of CP-99,219, a new fluoroquinolone, against isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:366-370.
9. Evans, M. E., and W. B. Titlow. 1998. Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin. Antimicrob. Agents Chemother. 42:727.
10. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
11. Ferrero, L., B. Cameron, B. Manse, D. Lagneau, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV. Mol. Microbiol. 13:641-653.
12. Fitzgibbon, J. E., J. F. John, J. L. Delucia, and D. T. Dubin. 1998. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2122-2124.
13. Fournier, B., and D. C. Hooper. 1998. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrob. Agents Chemother. 42:121-128.
14. Franke, A. E., D. E. Danley, F. S. Kaczmarek, S. J. Hawrylik, R. D. Gerard, S. E. Lee, and K. F. Geoghegan. 1990. Expression of human plasminogen activator inhibitor type-1 (PAI-1) in E. coli as a soluble protein comprised of active and latent forms. Biochim. Biophys. Acta 1037:16-27.
15. Fukuda, H., and K. Hiramatsu. 1999. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:410-412.
16. George, J., and I. Morrissey. 1998. Activity of levofloxacin, ofloxacin, ciprofloxacin, and sparfloxacin against DNA gyrase from S. pneumoniae C3LN4, abstr. C-176, p. 120. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
17. Gootz, T., R. Zaniewski, S. Haskell, B. Schmieder, J. Tankovic, D. Girard, P. Courvalin, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40:2691-2697.
18. Gootz, T. D., and K. E. Brighty. 1998. Chemistry and mechanism of action of the quinolone antibacterials, p. 29-80. In V. T. Andriole (ed.), The quinolones, 2nd ed. Academic Press, Inc., San Diego, Calif.
19. Gootz, T. D., K. E. Brighty, M. R Anderson, B. J. Schmeider, S. L. Haskell, J. A. Sutcliffe, M. J. Castaldi, and P. R. McGuirk. 1994. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diagn. Microbiol. Infect. Dis. 19:235-243.
20. Gootz, T. D., S. Haskell, and R. Zaniewski. 1997. Comparison of ciprofloxacin, trovafloxacin, and sparfloxacin for selecting topoisomerase II mutations in Streptococcus pneumoniae, abstr. P315, p. 68. In Program and abstracts of the 8th European Congress of Clinical Microbiology and Infectious Diseases.
21. Goss, W. A., W. H. Dietz, and T. M. Cook. 1965. Mechanism of action of nalidixic acid on Escherichia coli. J. Bacteriol. 89:1068-1074.
22. Guirard, B. M., and E. E. Snell. 1981. Biochemical factors in growth, p. 95. In P. Gerhardt, R. G. E. Murray, R. N. Costilow, E. W. Nester, W. A. Wood, N. R. Krieg, and G. B. Phillips (ed.), Manual of methods for general bacteriology. American Society for Microbiology, Washington, D.C.
23. Hallett, P., A. J. Grimshaw, D. B. Wigley, and A. Maxwell. 1990. Cloning of the DNA gyrase genes under tac promoter control: overproduction of gyrase A and B proteins. Gene 93:139-142.
24. Kaatz, G., and S. Seo. 1998. Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 42:197-198.
25. Kaatz, G., S. Seo, and C. Ruble. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37: 1086-1094.
26. Leggiadro, R. J. 1997. The clinical impact of resistance in the management of pneumococcal disease. Infect. Dis. Clin. N. Am. 11:867-874.
27. Margerrison, E. E. C., R. Hopewell, and L. M. Fisher. 1992. Nucleotide sequencing of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. J. Bacteriol. 174:1596-1603.
28. Morrissey, I., and J. T. George. 1998. The unique equipotency of sitafloxacin against topoisomerase IV and DNA gyrase from Streptococcus pneumoniae, p. 55. In Program and abstracts of the 6th International Symposium on New Quinolones.
29. Ng, E. Y., M. Truckiss, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888.
30. Pan, X.-S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin. Antimicrob. Agents Chemother. 41:471-474.
31. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
32. Schmitz, F.-J., M. E. Jones, B. Hofman, B. Hansen, S. Scheuring, M. Lückefahr, A. Fluit, J. Verhoef, V. Hadding, H.-P. Heinz, and K. Köhrer. 1998. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob. Agents Chemother. 42:1249-1252.
33. Sefton, A. M., J. P. Maskell, A. M. Rafay, A. Whiley, and J. D. Williams. 1997. The in vitro activity of trovafloxacin, a new fluoroquinolone, against gram-positive bacteria. J. Antimicrob. Chemother. 39(Suppl. B):57-62.
34. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1994. Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob. Agents Chemother. 38:2471-2476.
35. Sreedharan, S., M. Oram, B. Jensen, L. Peterson, and L. M. Fisher. 1990. DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli. J. Bacteriol. 172:7260-7262.
36. Takahata, M., M. Yonezawa, S. Kurose, N. Futakuchi, N. Matsubara, Y. Watanabe, and H. Narita. 1996. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistanl Staphylococcus aureus. J. Antimicrob. Chemother. 38:543-546.
37. Takenouchi, T., C. Ishii, M. Sugawara, Y. Yokue, and S. Ohya. 1995. Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob. Agents Chemother. 39:1414-1418.
38. Teng, R., T. E. Liston, and S. C. Harris. 1996. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J. Antimicrob. Chemother. 37:955-963.
39. Thornsberry, C., P. Ogilvie, J. Kahn, and Y. Mauriz. 1997. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn. Microbiol. Infect. Dis. 29:249-257.
40. Visalli, M. A., M. R. Jacobs, and P. C. Appelbaum. 1996. Activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin, and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology. J. Antimicrob. Chemother. 37:77-84.
41. Woodcock, J. M., J. M. Andrews, F. J. Boswell, N. P. Brenwald, and R. Wise. 1997. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. 41:101-106.
42. Yamagishi, J., T. Kojima, Y. Oyamada, K. Fujimoto, H. Hattori, S. Nakamura, and M. Inoue. 1996. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1157-1163.